Jennifer Hadlock, Andrew Magis and Chengzhen Dai

COVID-19 Outcome Disparities Across Racial/Ethnic Lines

ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.

COVID-19 Outcome Disparities Across Racial/Ethnic Lines
COVID-19 Outcome Disparities Across Racial/Ethnic Lines

Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers

GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.

Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers
Inside the intense world of COVID-19 science, and unexpected findings from Seattle researchers
Illustration of a person using a katana to slash a coronavirus in half

COVID-19 Immune Response Study Could Lead to More Effective Treatments

Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar. 

COVID-19 Immune Response Study Could Lead to More Effective Treatments
COVID-19 Immune Response Study Could Lead to More Effective Treatments
View of the responsive recruitment website and electronic consent platform as seen on mobile phone and desktop devices.

ISB Builds Digital Platform for COVID-19 Research Study – and Beyond

In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.

ISB Builds Digital Platform for COVID-19 Research Study – and Beyond
ISB Builds Digital Platform for COVID-19 Research Study – and Beyond
Illustration of a person using a katana to slash a coronavirus in half

Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19

ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.

Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19
Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19
1 2